Stoptions.aiStoptions.aiStoptions.aiStoptions.aiStoptions.ai
Powered by Amora Edge
How it worksResultsPricingMeet StoptieCompareBlog
Sign inStart free trial
Stoptions.ai
Powered by Amora Edge

Algorithmic scanning across the S&P 500 & Nasdaq 100. Stock & Options trade cards in your inbox by 9:35 AM ET every trading day.

Product
  • How it works
  • The Algorithm
  • Ticker Setups
  • Pricing
  • Morning Brief
  • Results
  • Compare tools
Account
  • Sign in
  • Start free trial
  • Give a gift
  • Dashboard
  • Settings
Company
  • About
  • Contact
  • Support
  • Blog
  • Sitemap
Legal
  • Terms of service
  • Privacy policy
  • Risk disclosure
  • Unsubscribe

© 2026 Stoptions.ai · All Rights Reserved

Not financial advice. Algo-generated setups are not personalised investment advice. Options trading involves significant risk of loss — past performance does not guarantee future results.

Chat with Stoptie
Stoptions.ai›Tickers›COR
Last updated: Mon May 11, 2026 · 9:31 AM ET
↻ Next update: Thu May 15, 2026 · 9:31 AM ET

COR Stock and Options Trade Setup — Cencora Inc.COR logo

NYSE · S&P 500 · Pharmaceutical Distribution & Services · Moderate liquidity options · Large cap · ~$52B

▲ Bullish setupHealthcareDistributionDefensiveLow risk↑ Score +4 vs last update
67
Amora Edge Score
67
Top 33% of today's scan
↑ +4 vs last update
Composite of EMA, RSI, RS vs SPY & volume · updated every 72h
64
COR Win Rate
64%
9 of 14 COR setups hit target in the last 6 months
Tracks completed Stoptions setups on this ticker since Jan 2026
Why we cover COR

Pharmaceutical distribution is an oligopolistic, volume-driven business with near-indestructible economics: Cencora, McKesson, and Cardinal Health collectively control ~90% of U.S. drug distribution. Switching costs are prohibitive, contracts are multi-year, and the fee-for-service model means Cencora benefits from rising drug prices without bearing drug pricing risk. The specialty pharma segment — oncology, immunology, rare disease — is growing faster than generics and carries higher margins. GLP-1 drug distribution volumes are adding a new high-growth layer as semaglutide adoption accelerates across the U.S. Cencora is also expanding internationally through its Alliance Healthcare operations in Europe. Free cash flow generation is exceptional, and the company has returned $2B+ annually to shareholders via buybacks and dividends. In any economic environment, people take their medications — making this a true recession-proof business.

Score History & Signal Changelog

Preview data

This page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.

Score progression across 4 updates
Solid = composite · dashed = components
Signal changelog
DateUpdateScoreDeltaKey change
Apr 27#1 Created57—Page created. GLP-1 distribution volumes adding to specialty pharma growth.
May 3#2 Update61+4Defensive rotation driving healthcare sector buying.
May 7#3 Update64+3Alliance Healthcare European contribution growing. FCF guidance raised.
May 11#4 Current67+3Consistent signal progress. Oligopoly moat narrative intact.

Signal Breakdown

EMA Cross
Holding
17/25
Above both EMAs; defensive trend intact despite low beta drift
RSI Zone
Holding
17/25
RSI at 55 — steady momentum consistent with low-volatility compounder
RS vs SPY
Holding
17/25
Outperforming XLV modestly; healthcare defensive rotation supporting
Volume Surge
Holding
16/25
Steady institutional volume; consistent long-only fund accumulation pattern

Today's Trade Card

Setup
COR $290 CALL
Expires Jun 20, 2026
Premium
$6.80
Target
+70% premium
Stop loss
-50% premium
Breakeven
$296.8
Win prob.
40%
Sizing: Risk ≤ 1% of account
Greeks
Delta
0.36
Theta
-0.14
IVR
24%
IVR class
Low
Trade card available on Pro & Elite
Or start free trial →

Options Profile

Avg IV (30d)
18%
IVR range (52-wk)
12–38%
Put/call ratio
0.62
Avg daily vol.
3.4K contracts
Open interest
52K contracts
Next earnings
Aug 7, 2026 (est.)

Risks & Fundamentals

Every setup carries risk. Here's what could move COR against you, plus the key stats that frame any position.

Beta
0.5
Market cap
~$52B
Risk level
Low risk
Next earnings
Aug 7, 2026 (est.)
Key risks to monitor
  • 1.Drug pricing reform legislation could restructure distributor economics if passed
  • 2.Opioid settlement liabilities — though substantially reserved — remain a tail risk
  • 3.Generic drug pricing deflation compresses volume-based margin contribution
These are real risks to the long thesis, not a recommendation to short. Stoptions setups are short-dated and stop-protected; size accordingly.

COR Options Setup — Frequently Asked Questions

Is COR a good options trade today?+

Cencora Inc. (COR) currently has an Amora Edge Score of 67/100, ranking it top 33% of today's scan. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.

What is COR's win rate on Stoptions.ai setups?+

COR's historical win rate on closed Stoptions setups is 64%. Win rate is calculated as the percentage of past COR trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.

What strike and expiry does Stoptions.ai suggest for COR?+

The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.

How often is the COR setup updated?+

Every 72 hours we refresh COR's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If COR drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.

What does the Amora Edge Score measure for COR?+

The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to COR: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is COR outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. COR currently scores 67.

How does COR compare to other Pharmaceutical Distribution & Services setups?+

COR's sector rank and percentile against other Pharmaceutical Distribution & Services tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Pharmaceutical Distribution & Services Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.

Educational content only — not personalized investment advice. Options carry substantial risk.

The Weekly · Free

Get a Friday recap including setups like COR.

Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.

No spam. One email Friday afternoon. Unsubscribe in one click.

More from Stoptions.ai
← All tickersHow the algorithm worksMorning BriefResultsPricing